US 12,186,324 B2
Imidazopiperazine inhibitors of transcription activating proteins
Kang Le, Sugar Land, TX (US); Michael J. Soth, Sugar Land, TX (US); Philip Jones, Houston, TX (US); Jason Bryant Cross, Pearland, TX (US); Christopher L. Carroll, Houston, TX (US); Timothy Joseph McAfoos, Pearland, TX (US); and Pijus Kumar Mandal, Sugarland, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on May 21, 2021, as Appl. No. 17/327,217.
Application 17/327,217 is a continuation of application No. 16/370,404, filed on Mar. 29, 2019, granted, now 11,058,688.
Claims priority of provisional application 62/650,151, filed on Mar. 29, 2018.
Prior Publication US 2023/0008047 A1, Jan. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 487/04 (2006.01); A61K 31/4985 (2006.01); A61K 31/5377 (2006.01); C07D 471/04 (2006.01); C07D 495/04 (2006.01)
CPC A61K 31/5377 (2013.01) [A61K 31/4985 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 495/04 (2013.01)] 26 Claims
 
1. A compound of structural Formula III

OG Complex Work Unit Chemistry
or a salt thereof, wherein:
R1 is chosen from alkyl, cycloalkyl and heterocycloalkyl;
R2 is chosen from —CH3, —CH2F, —NH2, —NHCH3, and —OCH3;
R4a and R4b are H;
W is chosen from C(R7a) and N;
X1 is independently chosen from C(R7b) and N;
X2 and X3 are independently chosen from C(H) and N;
Y and Z are independently chosen from C(H) and N;
R7a is chosen from H, alkyl, alkoxy, cyano, carboxy, halo, haloalkyl, hydroxy, and OXO;
R7b is chosen from H and fluoro;
R8 is chosen from aryl, heteroaryl, and heterocycloalkyl, and is optionally substituted with 1, 2, or 3 R10 groups; and
each R10 is independently chosen from alkyl, cyclopropyl, methoxy, cyano, halo, difluoromethyl, trifluoromethyl, trifluoromethoxy, hydroxy, CONH2, and CONHCH3.